Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$17.62
▼ $0.06 (-0.3%)
Market data updated: 09/19 06:07 AM
Fundamentals updated: 09/18/2026
News analyzed: 09/19/2026
Market Cap
Not available
Day Range
$17.37 - $17.95
52-Week Range
$12.99 - $25.59
Beta
—
Next Earnings
02.11.2026
Support
$17.20
Resistance
$25.17
SNDX is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
+19.9% (1Y)
Strengths: 6/30 factors positiveRisk: High
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🔴 Bearish
Technical Trend
🔴 Bearish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Revenue growth (last year)
Revenue growth (last year): 627.8%
Growth
Biggest negative driver
DCF Fair Value
Estimated fair value: -$97.67 vs. price $17.62 (-654.3%)
Fair Value
Signal tension
Growth scores strong (62/100), but fair-value analysis scores this stock as relatively expensive (38/100) — the growth story and the current price aren't fully aligned.
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
36
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
62
Quality
58
Value
38
Momentum
9
Risk
34
Sentiment
56
Fundamental
26
Institutional
0
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of Syndax Pharmaceuticals has focused on investor relations and stock market activity. The company announced inducement grants for new employees under its 2023 plan and participation in September investor conferences, including fireside chats at major biopharma events. Analysts like UBS adjusted their price target downward to $33 while maintaining a "Buy" rating, and Citi highlighted the stock as a potential high-growth pick. Despite nearly doubling revenue to $115 million in a quarter, the stock saw a slight decline, prompting analysis of investor sentiment beyond top-line figures.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Syndax Pharmaceuticals, Inc.. News trend score: 56. Reason: 6 of the last 20 articles are positive, versus 5 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
21
🎯 Conviction (vs. Emotion)
65
Psychology
46
Fundamentals
26
Technical
9
Valuation
38
The price is holding at a real, documented historical support/resistance level (a 50-day high or low).
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
Extreme momentum, price far above its moving average, and a large premium over fair value.
Price (3M)
-7%
Market Narrative
37
Fundamental Reality
65
Narrative Gap
-28
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
The market behavior for SNDX suggests a dominant **herding** dynamic, where traders appear to be aligning with peer declines rather than acting on isolated signals. The narrative-reality gap (-17) hints at a disconnect between market sentiment and fundamentals, but the absence of extreme volatility or sentiment extremes keeps panic or euphoria muted. Key open questions include whether the relative underperformance is structural or temporary, and if traders will double down on herding or reassess fundamentals. The lack of anchoring or loss aversion signals suggests no immediate defensive positioning, but the overconfidence score hints at potential complacency about fundamentals.
Updated: 09/09/2026, 09:10 AM
What could change this?
👥 What the crowd believes
"UBS analyst David Dai maintains Syndax Pharmaceuticals with a Buy and lowers the price target from $37 to $33."
"Syndax Pharmaceuticals posted a quarter that nearly doubled revenue, yet shares slipped 2.41%."
"Syndax management team will participate in Citi 2026 Biopharma Back to School Conference and H.C. Wainwright 28th Annual Global Healthcare Conference."
📈 13D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Charles Mackay — 99/100
🔴 Weakest match
Morgan Housel — 0/100
🗣️ Why do they disagree?
This stock divides the historical methodologies sharply, with some approaches seeing it as a cautious buy and others as a high-risk or outright poor fit. Charles Mackay’s near-perfect score suggests no signs of speculative mania, while Howard Marks (Market Cycle) views it as early-to-mid cycle, avoiding overextension concerns. In contrast, Fisher, Graham, and Loeb all flag significant red flags—Fisher dismisses it for lacking his signature quality/growth traits, Graham’s defensive criteria are ignored, and Loeb warns of unacceptable risk. Meanwhile, mid-tier signals from Lynch, Schwager, and Marks (general) reflect mixed views, with growth present but prices already pricing it in. At the extreme ends, Veblen and Housel reject it outright—Veblen sees it as growth-chasing without substance, while Housel’s zero score warns of volatility that would deter patient investors. The divergence highlights a spectrum from cautious optimism (Mackay, Marks Cycle) to outright rejection (Graham, Loeb, Housel).
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 99
No obvious signs of crowd mania
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟢 97
Cycle position looks favorable — closer to oversold than overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟢 81
Looks early-to-mid cycle, not overextended
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟢 73
A real, disciplined setup with favorable reward/risk
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🟢 69
Adequate but not exceptional liquidity
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 57
Mixed — a good business, but expectations may already be high
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🟡 55
Mixed — growth exists but the price already reflects much of it
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟡 48
Doesn't show the quality/growth signature Fisher required
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟡 48
Reasonable but not a clear long-term holding
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟡 44
Not statistically cheap enough for the Enterprising Investor's looser safety bar
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🔴 34
Weak case — Malkiel/Bogle would say a low-cost index is the simpler bet
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🔴 30
Fails most of Graham's defensive criteria
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🔴 29
Risk profile Loeb would flag as a real threat to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🔴 21
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🔴 21
Pattern Veblen would flag as growth pursued for its own sake
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 0
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Based on the last 279 trading days, calculated from real price data. Click an indicator for details and a chart.
🔴 Most indicators support a downtrend (0 bullish · 11 bearish · 0 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear downtrend with no defined trading range in the period examined.
Medium confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
—
Operating Margin
-158.4%
Net Margin
-165.6%
EBITDA Margin
-158.4%
ROE
-441.6%
ROA
-53.9%
ROIC
—
EPS
-$3.29
Cash
$134.93M
Total Debt
$350.00M
Current Ratio
4.40
Debt/Equity
5.42
How is Fair Value calculated? →
Current Price
$17.62
Estimated Fair Value (DCF)
-$97.67
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
-654.3%
🔴 Appears expensive relative to estimated value
Year 1 Growth Rate
25.0%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | 25.0% | $-403.96M | $-370.60M |
| 2 | 19.4% | $-482.23M | $-405.88M |
| 3 | 13.8% | $-548.53M | $-423.57M |
| 4 | 8.1% | $-593.10M | $-420.17M |
| 5 | 2.5% | $-607.93M | $-395.11M |
Base FCF (last actual year)
$-323.17M
Terminal Value
$-9.59B
Present Value of Terminal Value
$-6.23B
Enterprise Value
$-8.25B
Net Debt
$215.07M
Equity Value
$-8.46B
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$0.75
Tangible Book Value per Share (Tangible NAV)
$0.75
Sentiment based on basic keywords (not AI) — 6 positive, 9 neutral, 5 negative out of the last 20 articles.
SeekingAlpha · 10.9.2026
GlobeNewswire · 4.9.2026
Yahoo · 4.9.2026
Yahoo · 1.9.2026
GlobeNewswire · 1.9.2026
TipRanks · 22.8.2026
Yahoo · 22.8.2026
MT Newswires · 21.8.2026
Benzinga · 21.8.2026
Insider Monkey · 12.8.2026
Yahoo · 12.8.2026
Motley Fool · 12.8.2026
Yahoo · 12.8.2026
Benzinga · 11.8.2026
Simply Wall St. · 7.8.2026
GlobeNewswire · 5.8.2026
SeekingAlpha · 5.8.2026
GuruFocus.com · 5.8.2026
Benzinga · 5.8.2026
MarketBeat · 5.8.2026
Syndax Pharmaceuticals, Inc. (SNDX) currently has a StockIQ AI score of 36/100, rated "Weak". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
SNDX currently scores 36/100 (Weak) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
Per StockIQ's DCF model, SNDX's estimated fair value is -$97.67, which is 654.3% below the current price of $17.62. This is one valuation model among several signals in the fair-value category, not a price target.
SNDX's technical score is 9/100, which currently reads as bearish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Revenue growth (last year): 627.8%; Operating margin is stable or improving over time; Current ratio: 4.40.
Based on the real signals StockIQ computed: Estimated fair value: -$97.67 vs. price $17.62 (-654.3%); Operating margin: -158.4% (negative); Net margin: -165.6% (negative).
StockIQ has no recorded dividend payment history for SNDX.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 13 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Metzger Michael A | Exercise of Derivative Securities | 8.7.2026 | 32,375 | +32,375 | $6.38 |
| Metzger Michael A | Exercise of Derivative Securities | 8.7.2026 | 32,375 | +32,375 | — |
| Metzger Michael A | Open Market Sale | 8.7.2026 | 32,375 | -32,375 | $24.24 |
| Metzger Michael A | Exercise of Derivative Securities | 8.7.2026 | 517,218 | +32,375 | $6.38 |
| Metzger Michael A | Open Market Sale | 8.7.2026 | 484,843 | -32,375 | $24.24 |
| Metzger Michael A | Exercise of Derivative Securities | 8.7.2026 | 0 | +32,375 | — |
| Botwood Nicholas A.J. | Exercise of Derivative Securities | 12.6.2026 | 31,235 | +31,235 | $13.82 |
| Botwood Nicholas A.J. | Exercise of Derivative Securities | 12.6.2026 | 31,235 | +31,235 | — |
| Botwood Nicholas A.J. | Open Market Sale | 12.6.2026 | 31,235 | -31,235 | $18.14 |
| Botwood Nicholas A.J. | Exercise of Derivative Securities | 12.6.2026 | 92,120 | +31,235 | $13.82 |
| Botwood Nicholas A.J. | Open Market Sale | 12.6.2026 | 60,885 | -31,235 | $18.14 |
| Botwood Nicholas A.J. | Exercise of Derivative Securities | 12.6.2026 | 0 | +31,235 | — |
| Botwood Nicholas A.J. | Open Market Sale | 11.6.2026 | 34,280 | -34,280 | $18.00 |
| Botwood Nicholas A.J. | Exercise of Derivative Securities | 11.6.2026 | 22,515 | +22,515 | — |
| Botwood Nicholas A.J. | Exercise of Derivative Securities | 11.6.2026 | 22,515 | +22,515 | $13.82 |
| Botwood Nicholas A.J. | Exercise of Derivative Securities | 11.6.2026 | 95,165 | +22,515 | $13.82 |
| Botwood Nicholas A.J. | Open Market Sale | 11.6.2026 | 60,885 | -34,280 | $18.00 |
| Botwood Nicholas A.J. | Exercise of Derivative Securities | 11.6.2026 | 0 | +22,515 | — |
| Metzger Michael A | Open Market Sale | 1.6.2026 | 6,847 | -6,847 | $18.99 |
| Goldan Keith A. | Open Market Sale | 1.6.2026 | 1,177 | -1,177 | $18.99 |
| Metzger Michael A | Open Market Sale | 1.6.2026 | 484,843 | -6,847 | $18.99 |
| Goldan Keith A. | Open Market Sale | 1.6.2026 | 139,252 | -1,177 | $18.99 |
| Metzger Michael A | Open Market Sale | 9.2.2026 | 17,159 | -17,159 | $21.03 |
| Goldan Keith A. | Open Market Sale | 9.2.2026 | 3,410 | -3,410 | $21.03 |
| Goldan Keith A. | Open Market Sale | 9.2.2026 | 140,429 | -3,410 | $21.03 |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
21,681,907 shares short as of 2026-08-31 · vs. 22,665,216 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
45.0% of trading volume this week was short selling, vs. 57.2% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology